Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q1 2026 › vs Q1 2025
Tonix Pharmaceuticals Holding (TNXP) Q1 2026 vs Q1 2025 (year over year)
Tonix Pharmaceuticals Holding's revenue rose $4.4M (+183%) from $2.4M in Q1 2025 to $6.9M in Q1 2026. The biggest changes: Zembrace Symtouch +$904K (+45%); Tosymra −$186K (-46%).
Tonix Pharmaceuticals Holding, Q1 2026: revenue $6.9M (+183% year over year), operating margin -603.9%, net loss $40.2M, operating cash flow −$42.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Zembrace Symtouch | $2.9M | $2.0M | $904K | +45% |
| Tosymra | $217K | $403K | −$186K | -46% |
| Revenue | $6.9M | $2.4M | $4.4M | +183% |
| Other income, net | $1.3M | −$775K | $2.1M | — |
| Net loss | $40.2M | $16.8M | $23.4M | +139% |
| Costs & expenses | $48.4M | $19.3M | $29.2M | +151% |
| Operating costs | $48.4M | $18.5M | $29.9M | +162% |
| Cost of revenue | $1.6M | $943K | $635K | +67% |
| Research & development | $18.2M | $7.4M | $10.8M | +145% |
| SG&A | $28.6M | $10.1M | $18.5M | +183% |
| Operating cash sources | $44.8M | $18.0M | $26.9M | +150% |
| Depreciation & amortization | $555K | $493K | $62K | +13% |
| Share-based compensation | $2.0M | $882K | $1.1M | +123% |
| Cash used in operations | $42.3M | $16.6M | $25.7M | +155% |
| Net loss absorbed | $40.2M | $16.8M | $23.4M | +139% |
| Working capital & other | $4.6M | $1.1M | $3.5M | +313% |
Questions
How much did Tonix Pharmaceuticals Holding's revenue grow year over year in Q1 2026?
Tonix Pharmaceuticals Holding's revenue rose $4.4M (+183%) from $2.4M in Q1 2025 to $6.9M in Q1 2026.
What drove Tonix Pharmaceuticals Holding's revenue change in Q1 2026?
Zembrace Symtouch +$904K (+45%); Tosymra −$186K (-46%).